Sunshine Biopharma, Inc. (NasdaqCM: SBFM)
Health Care · Biotechnology · US
$0.22
-34.34% today · -98.9% 1Y
Sunshine Biopharma, Inc. (NasdaqCM: SBFM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $859.99K and employs 50 people.
Over the last twelve months the share price has lost 98.9%, trading between 0.19 and 23.20.
Tweenvest scores Sunshine Biopharma, Inc. across four factors: quality 51/100, value 36/100, growth 100/100. Its strongest factor is growth.
SBFM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $859.99K
- Revenue (TTM)
- $35.35M
- P/E
- —
- EPS
- -8.20
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $23.20
- 52-week low
- $0.19
- Avg volume (3M)
- —
- Shares outstanding
- 3.88M
- Employees
- 50
- Next earnings
- —
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
- ISIN
- US8677818093
- Listed since
- Feb 15, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Exousia Bio, Inc.OTCPK: LMMY | $918.75K | $0.02 | +10.06% |
| Aptahem AB (publ)NGM: APTA | $906.66K | Skr— | — |
| BioXcel Therapeutics, Inc.OTCPK: BTAI.Q | $904.73K | $0.03 | -29.51% |
| Yubo International Biotech LimitedOTCPK: YBGJ | $886.19K | $— | — |
| Epigenomics AGDB: ECX | $858.33K | €0.87 | -1.14% |
| Silexion Therapeutics CorpNasdaqCM: SLXN | $850.72K | $0.15 | -28.70% |
| Alligator Bioscience AB (publ)OM: ATORX | $837.19K | Skr0.01 | -13.73% |
| Agentix Corp.OTCPK: AGTX | $801.34K | $0.02 | — |
Figures last refreshed Oct 18, 2026.